SCHEMBL14051009

SCHEMBL14051009

CC(C)(C)OC(=O)NC1CN(c2cc(N)n3ncc(Br)c3n2)C1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 4/20 0.41
▸ PDPK1 O15530 4/20 0.41
▸ AURKB Q96GD4 4/20 0.41
▸ MAP4K4 O95819 2/20 0.41
▸ SUV39H2 Q9H5I1 6/20 0.40
▸ PDE10A Q9Y233 3/20 0.40
▸ BTK Q06187 2/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ CKS1B P61024 1/20 0.38
▸ SKP1 P63208 1/20 0.38
▸ SKP2 Q13309 1/20 0.38
▸ EIF2AK4 Q9P2K8 1/20 0.36
▸ CHEK1 O14757 1/20 0.36
▸ CCNA2 P20248 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CCNA1 P78396 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14050863 0.92 SUV39H2 (0.49) AURKAPDPK1AURKBMAP4K4SUV39H2
SCHEMBL14413680 0.87 PDE10A (0.41) AURKAPDPK1AURKBMAP4K4SUV39H2
SCHEMBL14050954 0.83 SUV39H2 (0.44) AURKAPDPK1AURKBMAP4K4SUV39H2
SCHEMBL14051004 0.82 PIM1 (0.43) BTKCKS1BSKP1SKP2CHEK1
SCHEMBL14051006 0.82 PIM1 (0.43) BTKCKS1BSKP1SKP2CHEK1
SCHEMBL14050800 0.80 PDE10A (0.47) AURKAPDPK1AURKBMAP4K4SUV39H2
SCHEMBL14050999 0.80 SUV39H2 (0.48) MAP4K4SUV39H2PDE10ABTKJAK3
SCHEMBL14413671 0.80 SUV39H2 (0.48) MAP4K4SUV39H2PDE10ABTKJAK3
SCHEMBL14413640 0.78 BTK (0.44) AURKAPDPK1AURKBMAP4K4SUV39H2
SCHEMBL14413674 0.78 CKS1B (0.51) SUV39H2PDE10ABTKJAK3CKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008130569-A1 NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2008-10-30 — — WO disclosed
Send feedback